The number of women considering pregnancy after breast cancer is
currently on the rise for several reasons. First, the incidence of
breast cancer is increasing in women of all ages, and 25% of all
breast cancer cases occur in premenopausal women. Second, many
women are delaying childbirth for personal, professional, or
educational reasons. Consequently, many premenopausal women are
facing breast cancer treatment before they have started or completed childbearing.
Recent reviews of breast cancer associated with pregnancy have
focused on the traditional definitionthat the cancer was
diagnosed during or within 1 year following pregnancy. Our review
looks at the problem from a different viewpoint. It explores the
various issues women face if they have ever had breast cancer and are
now either pregnant or considering pregnancy. These issues fall into
seven major categories: (1) sexual functioning, (2) infertility, (3)
congenital anomalies, (4) breast-feeding, (5) methods for monitoring
breast cancer recurrence, (6) risk of recurrent breast cancer, and
(7) antiestrogen therapy. A search of the English literature in OVID
from 1966 to 1997 forms the basis of this report.
Ever since psychological issues became a focus of attention in
oncology, breast cancer treatment has been seen as producing
significant sexual disruption.
Effects of Surgery
It was hoped that breast-conserving surgery or breast reconstruction
would have a clear, significant advantage over mastectomy in helping
women stay sexually active and functional, as well as psychologically
stable. This has not proved to be the case, however.
A womans overall psychological health, satisfaction with her
relationships, and premorbid sexual life appear to be stronger
predictors of sexual satisfaction after breast cancer treatment than
the extent of damage to her breast. In 12 studies that compared
quality of life after mastectomy with that after breast-conserving
surgery and radiotherapy, patients treated with breast conservation
consistently had more positive feelings about their bodies.
General psychological distress, psychiatric disorders, marital
happiness, frequency of sex, and sexual dissatisfaction, however,
were the same in the two groups. Bias may have been introduced if
women who cared most about their appearance declined to undergo
mastectomy, and yet studies that randomly assigned patients to
mastectomy or breast conservation showed similar results as the
As with breast conservation, breast reconstruction has its strongest
impact on improving body image.[6-9] The most common motivations for
breast reconstruction are to feel whole again, eliminate the need for
a breast prosthesis, and wear a wider variety of clothing.[7-9]
Effects of Systemic Therapy
Systemic treatment may also adversely affect sexual desire.
Lasting consequences of chemotherapy, such as weight gain, fatigue,
and change in the appearance of the hair, may decrease sexual desire
or performance. In a cross- sectional study of two large metropolitan
areas, tamoxifen (Nolvadex) had no impact on the sexual functioning
among women age 50 years and older.[10a] We need more information on
how chemotherapy and hormonal therapy affect womens sex lives.
Infertility is a prominent concern of many women considering
treatment for breast cancer. Breast cancer itself poses no known
threat to fertility. In addition, although surgery and radiation
treatment may impair a womans ability to breast-feed in the
future (see Breast-Feeding below), these modalities do
not decrease the likelihood of pregnancy.
Effects of Chemotherapy
Chemotherapy, on the other hand, has been shown to cause amenorrhea
in premenopausal females. Endocrine hormone profiles obtained in
premenopausal patients who developed drug-induced amenorrhea are
consistent with primary ovarian failure.[12-15] Estradiol and
progesterone levels remain consistently low and cease to show normal
cyclic changes, whereas the pituitary gonadotropins,
follicle-stimulating hormone (FSH) and luteinizing hormone (LH), are
elevated to postmenopausal levels. Serum dehydroepiandrosterone and
prolactin levels are not affected, which is consistent with intact
pituitary and adrenal function, respectively. Since adjuvant
chemotherapy is indicated in most women with early-stage breast
cancer, many premenopausal women face the possibility of
infertility before they have completed childbearing.
Several general conclusions can be drawn from recent reviews focusing
on the impact of chemotherapy on fertility[11,17,18]:
1) The chance of infertility is proportional to the age of the
patient (Table 1).[18-21] The
average age of menopause in US women is between 50 and 52 years. For
women treated with chemotherapy, the median age is 38 to 46 years.
Sutton et al studied FAC (fluoro-uracil, Adriamycin, and
cyclophosphamide) chemotherapy in women £ 35 years old. Of the
128 patients whose menstrual histories were known, 59% continued to
menstruate after chemotherapy, whereas 32% and 9% experienced
temporary and permanent amenor- rhea, respectively. In a study by
Dnistrian et al, two patients under age 30 years showed no evidence
of ovarian suppression after 24 cycles (2 years) of CMF
(cyclophosphamide, methotrexate, and fluorouracil) therapy.
2) Infertility is related to the type of chemotherapy. Alkylating
agents, specifically, cyclophosphamide (Cytoxan, Neosar), are more
likely to cause infertility than are nonalkylating agents. Alkylators
are believed to act on undeveloped oocytes and, possibly, on the
pregranulosa cells of primordial follicles.
The antibiotic doxorubicin, the antimetabolite cytarabine, and the
Vinca extract vinblastine also appear to be toxic to the germinal
epithelium. Most other antimetabolites, however, including
fluorouracil, methotrexate, and mercaptopurine (Purinethol), do not
appear to damage the germinal epithelium. There is little
clinical information on doxorubicin. In a study that compared MOPP
(mechlorethamine, Oncovin, procarbazine, and prednisone) and ABVD
(Adriamycin, bleomycin, vinblastine, and dacarbazine) in the
treatment of Hodgkins disease, ovarian failure occurred less
often in the ABVD group. In animal studies, doxorubicin has been
shown to cause testicular damage.
3) The risk of infertility increases as the total dose of
chemotherapy escalates. In younger women, higher cumulative doses are
needed to induce gonadal failure: The average dose of single-agent
cyclophosphamide before the onset of amenorrhea was 5,200 mg in
49-year-olds, 9,300 mg in 30-year-olds, and 20,400 mg in
20-year-olds. The higher rate of gonadal failure noted in older
women may be explained by the lower number of remaining follicles.
From 2,000,000 follicles at birth, 200,000 remain at puberty and
approximately 400 at menopause.
4) The effect of shorter durations of some currently used dose
regimens has not been adequately studied.[11,17,18] There is no
conclusive evidence that duration of treatment, dose intensity,
schedule, or route of administration are independent variables.
5) It may be difficult to discern whether authors are referring to
permanent or temporary amenorrhea. Little information is
available regarding reversibility. Bianco et al described women in
whom menstrual periods resumed from 4 to 29 months after breast
In the event that a woman becomes pregnant after breast cancer is
diagnosed and treated, her risk of bearing a child with congenital
anomalies appears to be no greater than that of the general
population. Most physicians recommend that a women wait 2 to 5 years
after breast cancer treatment before becoming pregnant. The primary
reason for this recommendation is that most recurrences of breast
cancer occur within the first 2 years of diagnosis. Also,
chemotherapy drugs demonstrate teratogenic effects if they are
administered during the first trimester of pregnancy.[27,28]
Limited data suggest that the administration of chemotherapy to
patients in the second or third trimester is not detrimental to the
fetus.[27,29] The multidrug-resistant P-glycoprotein has been found
in the gravid endometrium and may offer some protection to the fetus
from a drug such as doxorubicin.
The results of pregnancy following breast cancer diagnosis are shown
in Table 2.[21,31-33] The number of
elective abortions was much more common in early reports compared
to later studies, as pregnancy became more accepted after breast cancer.
A case-control study compared parents of children with a congenital
anomaly born between April 1979 and December 1986 with a matched
sample of parents of children without anomalies. This study found no
association between congenital anomalies in the offspring and any
type of cancer treatment in either the mother or father.
Little is known about the late effects of chemotherapy on offspring,
such as impaired physical growth, intellectual and neurologic
function, or gonadal function and reproductive capacity;
transplacental carcinogenesis, transplacental mutagenesis of
germ-line tissue; and secondary carcinogenesis.[11,35]
Mulvihill et al reported the results of a retrospective review of
pregnancy outcome among female patients treated for a variety of
advanced malignancies in Cancer and Leukemia Group B trials. A
total of 58 pregnancies occurred at a mean of 27 months after
chemotherapy (range, 2 to 104 months). In the first year after
chemotherapy, there were unexpected increases in low birthweight,
stillbirth, and premature termination of pregnancy, with no excess of
congenital anomalies. These effects reflect dysfunction in the milieu
required to maintain pregnancy, rather than damage of oocytes.
In a pregnant patient with metastatic cancer, the question arises of
possible hematogenous dissemination involving the products of
conception. Experimental studies of nonbreast tumors in animals hint
that this occurrence is quite unusual, and suggest that the low
frequency may be due to an ill-defined resistance of placental tissue
to metastatic tumor growth.[37,38]
Clinical reports confirm the rarity of this event. From 1866 to 1989,
there were only 52 cases in the western literature. Only
melanoma, leukemia, lymphoma, and one case of hepatocellular
carcinoma have caused fetal metastases. Of the 24 cases Potter and
Schoeneman collected from the world literature, there were 4
documented cases of metastasis from breast cancer to the placenta,
and only 1 case exhibited invasion of the chorionic villi; no fetal
involvement occurred, and all 4 children were reported to be disease-free.
1. Petrek JA: Breast cancer during pregnancy. Cancer 74:518-527, 1994.
2. Schover LR: The impact of breast cancer on sexuality, body image,
and intimate relationships. CA: Cancer J Clin 41:112-120, 1991.
3. Schain W, Edwards BK, Gorrell CR, et al: Psychosocial and physical
outcomes of primary breast cancer therapy: Mastectomy vs excisional
biopsy and irradiation. Breast Cancer Res Treat 3:377-382, 1983.
4. Fallowfield LJ, Baum M, Maquire GP: Effects of breast conservation
on psychological morbidity associated with diagnosis and treatment of
early breast cancer. Br Med J Clinic Res Ed 293:1331-1334, 1986.
5. Kemeny MM, Wellisch DK, Schain WS: Psychosocial outcome in a
randomized surgical trial for treatment of primary breast cancer.
Cancer 62:1231-1237, 1988.
6. Schain WS, Wellisch DK, Pasnau RO, et al: The sooner the better: A
study of psychological factors in women undergoing immediate versus
delayed breast reconstruction. Am J Psychiatry 142:40-46, 1985.
7. Noone RB, Frazier TG, Hayward CZ, et al: Patient acceptance of
immediate reconstruction following mastectomy. Plast Reconstr Surg
8. Stevens LA, McGrath MH, Druss RG, et al: The psychological impact
of immediate breast reconstruction for women with early breast
cancer. Plast Reconstr Surg 73:619-628, 1984.
9. Dean C, Chetty U, Forrest AP: Effects of immediate breast
reconstruction on psychosocial morbidity after mastectomy. Lancet
10. Andersen BL: How cancer affects sexual functioning. Oncology
10a. Ganz PA, Rowland JH, Desmond K, et al: Life after breast cancer:
Understanding womens health-related quality of life and sexual
functioning. J Clin Oncol 16:501-514, 1998.
11. Reichman BS, Green KB: Breast cancer in young women: Effect of
chemotherapy on ovarian function, fertility and birth defects. J Natl
Cancer Inst 16:125-129,1994.
12. Rose DP, Davis TE: Ovarian function in patients receiving
adjuvant chemotherapy for breast cancer. Lancet 1:1174-1176, 1977.
13. Dnistrian AM, Schwartz MK, Fracchia AA, et al: Endocrine
consequences of CMF therapy in premenopausal and postmenopausal
breast cancer patients. Cancer 51:803-807, 1983.
14. Samaan NA, DeAsis DN, Buzdar AU, et al: Pituitary-ovarian
function in breast cancer patients on adjuvant chemotherapy. Cancer
15. Koyama H, Wada T, Nishizawa Y, et al: Cyclophosphamide-induced
ovarian failure and its therapeutic significance in patients with
breast cancer. Cancer 39:1403-1409, 1977.
16. Goldhirsch A, Wood WC, Senn HJ, et al: Meetings highlights:
International consensus panel on the treatment of primary breast
cancer. J Natl Cancer Inst 87:1441-1445, 1995.
17. Collichio F, Pandya K: Amenorrhea following chemotherapy for
breast cancer: Effect on disease free survival. Oncology 8:45-52, 1994.
18. Bines J, Oleske DM, Cobleigh MA: Ovarian function in
premenopausal women treated with adjuvant chemotherapy for breast
cancer. J Clin Oncol 14:1718-1729, 1996.
19. Hortobagyi GN, Buzdar AU, Marcus CE, et al: Immediate and long
term toxicity of adjuvant chemotherapy regimens containing
doxorubicin in trials at M. D. Anderson Hospital and Tumor Institute.
NCI Monogr 1:105-109, 1986.
20. Fisher B, Sherman B, Rockette H, et al: L-phentolamine mustard
(L-PAM) in the management of premenopausal patients with primary
breast cancer: Lack of association of disease-free survival with
depression of ovarian function; National Surgical Adjuvant Project
for Breast and Bowel Cancers. Cancer 44:847-857, 1979.
21. Sutton R, Buzdar AU, Hortobagyi GN: Pregnancy and offspring after
adjuvant chemotherapy in breast cancer patients. Cancer 39:1403-1409, 1977
22. Sobrinho LG, Levine RA, DeConti RC: Amenorrhea in patients with
Hodgkins disease treated with antineoplastic agents. Am J
Obstet Gynecol 109:135-139, 1971.
23. Waxman J: Chemotherapy and the adult gonad: A review. J R Soc Med
24. Santoro A, Bonadonna G, Valagussa P, et al: Long term results of
combined chemotherapy-radiotherapy approach in Hodgkins
disease: Superiority of ABVD plus radiotherapy versus MOPP plus
radiotherapy. J Clin Oncol 5:27-37, 1987.
25. Damewood MD, Grochow LB: Prospects for fertility after
chemotherapy or radiation for neoplastic disease. Fertil Steril
26. Bianco AR, Del Mastro L, Gallo C, et al: Prognostic role of
amenorrhea induced by adjuvant chemotherapy in premenopausal patients
with early breast cancer. Br J Cancer 63:799-803, 1991.
27. Zemlickis D, Lishner M, Degendorfer, et al: Fetal outcomes after
in utero exposure to cancer chemotherapy. Arch Intern Med
28. Wiebe VJ, Sipila PE: Pharmacology of antineoplastic agents in
pregnancy. Crit Rev Oncol Hematol 16:75-112, 1994.
29. Aviles A, Diaz-Maqueo JC, Talavera A, et al: Growth and
development of children of mothers treated with chemotherapy during
pregnancy: Current status of 43 children. Am J Hematol 36:243-248, 1991.
30. Bruner JA: Current Clinical Practice. Adjuvant chemotherapy for
breast cancer in pregnancy: Can recommendations be made with
confidence? Semin Oncol 24:35-36, 1997.
31. Ribeiro G, Jones DA, Jones M: Carcinoma of the breast associated
with pregnancy. Br J Surg 73:607-609, 1986.
32. Malamos NA, Stathopoulos GP, Keramopoulos A et al : Pregnancy and
offspring after the appearance of breast cancer. Oncology 53:471-475, 1996.
33. Dow KH, Harris JR, Roy C: Pregnancy after breast conserving
surgery and radiation therapy for breast cancer. Natl Cancer Inst
Monogr 16:131-137, 1994.
34. Dodds L, Marrett LD, Tomkins DJ, et al: Case-controlled study of
congenital anomalies in children of cancer patients. Br Med J
35. Hawkins MM: Is there evidence of a therapy-related increase in
germ cell mutation among childhood cancer survivors? J Natl Cancer
Inst 83:1643-1650, 1991.
36. Mulvihill, JT, McKeen EA, Rosner F, et al: Pregnancy outcome in
cancer patients: Experience in large cooperative groups. Cancer
37. Retic A, Sabesin S, Hume R, et al: Experimental transmission of
malignant melanoma cells through the placenta. Surg Gyncol Obstet
38. Pang C: Transplacental metastasis of Brown-Pearce rabbit tumors.
Bull Tulane Med Fac 17:31, 1957.
39. Dildy GA, Moise KJ, Carpenter RJ, et al: Maternal malignancy
metastatic to the products of conception: A review. Obstet Gynecol
Surv 44:535-40, 1970.
40. Potter JF, Schoeneman M: Metastases of maternal cancer to the
placenta and fetus. Cancer 25:380-388, 1970.
41. Green JP: Post-irradiation lactation. Int J Radiat Oncol Biol
Phys 17:244, 1989.
42. David FC: Lactation following primary radiation therapy for
carcinoma of the breast. Int J Radiat Oncol Biol Phys 11:1425, 1985.
43. Findlay PA, Gorrell CR, DAngelo T, et al: Lactation after
breast irradiation. Int J Radiat Oncol Biol Phys 15:511-514, 1988
44. Wobbes TH: Effect of breast saving procedure on lactation. Eur J
Surg 162:419-420, 1996.
45. Byers T, Graham S, Rzepka T, et al: Lactation and breast cancer:
Evidence for negative association in premenopausal woman. Am J
Epidemiol 121:664-674, 1985.
46. Michels KB, Willett WC, Rosner BA, et al: Prospective assessment
of breastfeeding and breast cancer incidence among 89,887 women.
Lancet 347:431-36, 1996
47. McTiernan A, Thomas DB. Evidence for a protective effect of
lactation on risk of breast cancer in young women: Result from a case
control study. Am J Epidemiol 124:353-358, 1986.
48. Newcomb PA, Storer BE, Longnecker MP, et al: Lactation and a
reduced risk of premenopausal breast cancer. N Engl J Med 330:81-87, 1994.
49. Dewailly E, Ayotte P, Brisson J: Protective effect of breast
feeding on breast cancer and body burden of carcinogenic
organochlorines. J Natl Cancer Inst 86:803, 1994.
50. American Society of Clinical Oncology: Recommended breast cancer
surveillance guidelines. J Clin Oncol 15:2149-2156, 1997.
51. Ishida T, Yokoe T, Kasumi F et al: Clinicopathologic
characteristics and prognosis of breast cancer patients associated
with pregnancy and lactation: Analysis of case control study in
Japan. Jpn J Cancer Res 83:1143-1149, 1992.
52. Wallack MK, Wolf JA, Bedwinek J, et al: Gestational carcinoma of
the female breast. Curr Prob Cancer 7:1-58, 1983.
53. Duncan KR: The development of magnetic resonance imaging in
obstetrics. Br J Hosp Med 55:178-181, 1996.
54. Henderson BE, Bernstein L: Etiology and pathogenesis of breast
cancer: Endogenous and exogenous hormonal factors, in Harris JR,
Lippman MZ, Marrow M, et al (eds): Diseases of the Breast, pp
185-200. New York, Lippincott-Raven, 1996.
55. Kroman N, Jensen MB, Melbyem, et al: Should women be advised
against pregnancy after breast cancer treatment? Lancet 350:319-322, 1997.
56. Danforth D: How subsequent pregnancy affects outcome in women
with a prior cancer. Oncology 5:23-30, 1991.
57. Clark RM, Ried J: Carcinoma of the breast in pregnancy and
lactation. Int J Radiat Oncol Biol Phys 4:693-698, 1978.
58. Schoultz E, Johansson H, Wilking N, et al: Influence of prior and
subsequent pregnancy on breast cancer prognosis. J Clin Oncol
59. Cooper DR, Butterfield J: Pregnancy subsequent to mastectomy for
cancer of the breast. Ann Surg 171:429-433, 1969.
60. Sankilar, Heinavaara S, Hakulinen T: Survival of breast cancer
patients after subsequent term pregnancy: Healthy mother
effect. Am J Obstet Gynecol 170:818-823, 1994.
61. Lethaby AE, ONeill MA, Mason BH et al: Overall survival
from breast cancer in women pregnant or lactating at or after
diagnosis. Int J Cancer 67:75-755, 1996.
62. Mignot L, Morvan F, Sarrazin D, et al: Breast cancer and
subsequent pregnancy (abstract). Proc Am Soc Clin Oncol 5:57, 1986.
63. Ariel IM, Kempner R: The prognosis of patients who become
pregnant after mastectomy for breast cancer. Int Surg 74:185-187, 1989.
64. Petrek JA, Dukoff R, Rogatko A: Prognosis of pregnancy-associated
breast cancer. Cancer 67:869-872, 1991.
65. Ingle JN, Ahmann DL, Green SJ et al: Randomized clinical trial of
diethylstilbestrol versus tamoxifen in postmenopausal women with
advanced breast cancer. N Engl J Med 304:16-21, 1981.
66. Formby B: Immunologic response in pregnancy: Its role in
endocrine disorder of pregnancy and influence on the course of
maternal autoimmune diseases. Endocrinol Metab Clin North Am 24:187-205,
67. Gleicher N, Siegel I: Common denominators of pregnancy and
malignancy. Prog Clin Biol Res 70:339-353,1981.
68. Patterson J, Furr B, Wakeeling A, et al: The biology and
physiology of Nolvadex (tamoxifen) in the treatment of breast cancer.
Breast Cancer Res Treat 2:363-374, 1982.
69. Powles TJ, Hickish T, Kanis JA, et al: Effect of tamoxifen on
bone mineral density measured by x-ray absorptiometry in healthy
premenopausal and postmenopausal women. J Clin Oncol 14:78-84, 1996.
70. Love RR, Newcomb PA, Wiebe DA et al: Effects of tamoxifen therapy
on lipid and lipoprotein levels in postmenopausal patients with
node-negative breast cancer. J Natl Cancer Inst 82:1327-1332, 1990.
71. Cohen CJ: Tamoxifen and endometrial cancer: Tamoxifen effects on
the female genital tract. Semin Oncol 24(1):S1-55-S1-64, 1997.
72. Fisher B, Constantino JP, Pedmont CK et al: Endometrial cancer in
tamoxifen-treated breast cancer patients: Findings from NSABP B-14. J
Natl Cancer Inst 86:527-537, 1994.
73. Jaiysimi IA, Buzdar AU, Decker DA et al: Use of tamoxifen for
breast cancer: Twenty-eight years later. J Clin Oncol 13:513-529, 1995.
74. Jordan CV, Fritz NF, Langan-Fahey S, et al: Alteration of
endocrine parameters in premenopausal women with breast cancer during
long-term adjuvant therapy with tamoxifen as a single agent. J Natl
Cancer Inst 83:1488-1491, 1991.
75. Manni A, Pearson, OH: Antiestrogen-induced remissions in
premenopausal woman with stage IV breast cancer: Effects on ovarian
function. Cancer Treat Reports 64:779-785, 1980.
76. Chibbar R, Wong S, Miller FD, et al: Estrogen stimulates oxytocin
gene expression in human chorio-decidua. J Clin Endocrinol Metab
77. Sharma SC, Purohit P, Rao AJ: Role of oestradiol-17 beta in the
regulation of synthesis and secretion of human chorionic
gonadotrophin by first trimester human placenta. J Mol Endocrinol
78. Urabe M, Chetrite G, Pasqualini JR: Transformation of estrone,
estradiol, and estrone sulfate in uterine and vaginal isolated cells
of fetal guinea pig. Effect of various antiestrogens in the
conversion of estrone sulfate to estradiol. Steroids 58:209-14, 1993 .
79. Wisel MS, Datta JK, Saxena RN: Effects of anti-estrogens on early
pregnancy in guinea pigs. Int J Fertil Menopausal Stud 39:156-163, 1994.
80. Lai CH, Hsueh S, Chao AS, et al: Successful pregnancy after
tamoxifen and megestrol acetate therapy for endometrial carcinoma. Br
J Obstet Gynaecol 101:547-549, 1994.